Diabetes Therapy
Muraglitazar improved glycemic control, triglycerides, and HDL cholesterol in type 2 diabetes
Published in Obesity and Diabetes Week, June 26th, 2006
According to recent research from the United States, "We sought to evaluate the effects of muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor (PPAR) activator within the new glitazar class, on hyperglycemia and lipid abnormalities."
"A double-blind, randomized, controlled trial was performed in 1,159 patients with type 2 diabetes inadequately controlled with metformin. Patients received once-daily doses of either 5 mg muraglitazar or 30 mg pioglitazone for a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes & Obesity
Amino acids need glucose to enhance insulin-activated PKB cascade in insulin-resistant adipocytes - Diabetes Epidemiology
Adipose triglyceride lipase gene is linked to FFA, triglycerides, and type 2 diabetes - Obesity Pathogenesis
NFATc4 and ATF3 negatively regulate adiponectin gene expression in 3T3-L1 adipocytes - Business Update
Cordis announces nationwide introduction of devices to treat artery blockages in leg - Business Update
EuroPharma appointed exclusive U.S. distributor of new omega-3 with high absorption level - Business Update
Rohto announces exclusive rights agreement with Dynamis Therapeutics on Supplamine - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
